IL15 and B-cell non-Hodgkin lymphoma: Another fusion protein, obtained by coupling an IL-15 superagonist mutant (IL-15N72D) to an IL-15Rα/IgG1-Fc (ALT-803 by Altor Bioscience Corporation), exhibited superior immunostimulatory activity, prolonged in vivo pharmacokinetics and increased in vivo biologic activity against B cell lymphoma and glioblastoma compared to IL-15 in mouse models [66,67].